Interim Chief Investment Officer
Robin Campbell, PhD has more than 30 years experience working with large companies (Shell Research, GSK), start-ups (Porton International, PafraBio) and in investment banking (including Credit Suisse, Jefferies). Roles in industry encompassed R&D, international strategic marketing, market access and business development.
Currently his specialty is searching out investable opportunities in the broader life sciences sector, and helping small companies raise growth capital. Robin has helped list a number of companies onto the AIM and international exchanges, advised companies on secondary fundraisings, private equity raises, M&A and has a broad reach into institutional and retail investor networks.
He has a degree in Microbiology from King’s College London, a Ph.D. in Immunobiology from Liverpool University and is FCA registered. Dr Campbell currently advises a number of private and listed businesses in respect to strategic and financial market opportunities.